Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O G Ottmann

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
Oncogene|April 29, 2009
Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndromeS Boehrer, L Adès, N Tajeddine, et al.
Annals of Hematology|November 9, 2002
Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemiaW K Hofmann, G Seipelt, S Langenhan, et al.
Leukemia|November 5, 2013
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patientsU Platzbecker, H K Al-Ali, N Gattermann, et al.
Leukemia|July 6, 2012
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II studyF J Giles, P D le Coutre, J Pinilla-Ibarz, et al.
Leukemia|November 24, 2012
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intoleranceE Jabbour, P D le Coutre, J Cortes, et al.
Leukemia|May 27, 2017
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blastsG Garcia-Manero, M A Sekeres, M Egyed, et al.
Leukemia|December 6, 2012
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemiaH Pfeifer, B Wassmann, W Bethge, et al.
Leukemia|October 3, 2003
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-CM C Müller, N Gattermann, T Lahaye, et al.
Leukemia|December 25, 2009
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008M Brüggemann, A Schrauder, T Raff, et al.
Leukemia|March 27, 2004
The German competence network 'Acute and chronic leukemias'R Hehlmann, U Berger, C Aul, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
Oncogene|April 29, 2009
Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndromeS Boehrer, L Adès, N Tajeddine, et al.
Annals of Hematology|November 9, 2002
Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemiaW K Hofmann, G Seipelt, S Langenhan, et al.
Leukemia|November 5, 2013
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patientsU Platzbecker, H K Al-Ali, N Gattermann, et al.
Leukemia|July 6, 2012
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II studyF J Giles, P D le Coutre, J Pinilla-Ibarz, et al.
Leukemia|November 24, 2012
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intoleranceE Jabbour, P D le Coutre, J Cortes, et al.
Leukemia|May 27, 2017
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blastsG Garcia-Manero, M A Sekeres, M Egyed, et al.
Leukemia|December 6, 2012
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemiaH Pfeifer, B Wassmann, W Bethge, et al.
Leukemia|October 3, 2003
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-CM C Müller, N Gattermann, T Lahaye, et al.
Leukemia|December 25, 2009
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008M Brüggemann, A Schrauder, T Raff, et al.
Leukemia|March 27, 2004
The German competence network 'Acute and chronic leukemias'R Hehlmann, U Berger, C Aul, et al.
Pageof 14